News and Updates

ULM, Germany—We officially kicked-off the Q-AID project with the first in-person meeting between the research partners from IBEC, University of Antwerp and our industry AI teams from Gemelli Biotech, Aarhus University, DPU and CEA.

Q-AID’s mission is to integrate quantum-enhanced hyperpolarized MRI imaging with advanced AI, opening new possibilities for diagnosis and treatment of cancer, Alzheimer’s disease, and multiple sclerosis.

As part of the European Commission’s Quantum Europe Strategy, Q-AID helps to position Europe as a global leader in quantum innovation.

Learn more about Q-AID ↗

MUNICH, Germany—NVision Imaging Technologies has been recognized as a Top 10 Finalist for The Spark - The German Digital Award (Der Deutsche Digitalpreis). The award committee recognized POLARIS for its new approach to medical diagnostics, applying quantum physics to solve a critical healthcare challenge.

Learn more ↗

ULM, Germany - We joined the annual General Assembly of QuE-MRT, for a day focused on discussions and updates for advancing metabolic imaging.

This German flagship project is focused on building an end-to-end clinical platform for quantum-enhanced hyperpolarized metabolic MRI, including R&D work on the polarizer and MRI acquisition methods, preclinical research on cancer models, regulatory effort towards clinical studies in Germany and ultimately running clinical studies on 3 different cancer patient populations.

Once again, we were impressed by the progress happening on so many fronts:
- Standardized MRI acquisition protocols enabling broader adoption
- New, promising metabolic probes (like Z-OMPD and α-KIC)
- Key advances in the regulatory process toward the first clinical HP-MRI studies in Germany

Learn more about QuE-MRT ↗

BRUSSELS, Belgium— The European Commission has formalized its Quantum Europe Strategy, listing Quantum-Enhanced MRI (Q-MRI) as a core priority for global leadership by 2030.

NVision's POLARIS platform provides the necessary room-temperature hyperpolarization technology to enable Q-MRI to be technically feasible and scalable in clinical settings. The alignment of POLARIS with this strategic mandate contributes to providing non-invasive, real-time metabolic insights as a "Made in Europe" quantum solution for global health.

Learn more ↗

LONDON, UK–POLARIS was temporarily installed at University College London (UCL) as part of CHARM (Calibration of Hyperpolarized metAbolic MR).CHARM is a UK–Germany collaboration involving Professor Shonit Punwani’s group at UCL, Professor Xavier Golay’s team at Gold Standard Phantoms, and NVision. The project aims to make hyperpolarized MRI scalable through standardized calibration methods, phantoms, and reliable polarizer technology.During the three-week deployment, POLARIS supported over 100 hyperpolarization experiments and demonstrated consistent performance.

BRUSSELS, Belgium— NVision announced its key role in the Q-AID consortium, a new EU initiative focused on integrating quantum-enhanced metabolic imaging with advanced AI tools for medical diagnostics.The consortium will use POLARIS technology to address needs in cancer, Alzheimer's disease, and multiple sclerosis by supporting earlier diagnosis and treatment monitoring.This multi-year program, supported by the European Commission, focuses on preclinical validation and small-scale clinical studies (20–70 patients).
‍Learn more about Q-AID ↗

MUNICH, Germany— The first installation of the POLARIS system at the Technical University of Munich's Schilling Lab is providing research data shortly after its launch.Researchers are using POLARIS to generate high-resolution metabolic data, with an initial focus on cardiac and renal metabolism.

ULM, Germany— NVision has launched the POLARIS Preclinical polarizer.This automated research tool employs proprietary quantum sensing technology to produce hyperpolarized MRI agents on-site, at scale.POLARIS Preclinical enables up to 100,000-fold signal enhancement of metabolic MRI by hyperpolarizing MRI imaging agents. Requiring no changes to the scanner, this capability effectively turns existing MRIs into powerful metabolic imagers.Because disease metabolism is fundamentally different from that of healthy tissue, this metabolic insight allows researchers to track therapeutic response in days, accelerating preclinical discovery and bridging the path to clinical implementation.

Learn more about the technical capabilities of POLARIS ↗